OnCo
termsTerm

MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶)

MRD negativity means no detectable myeloma cell among 100,000 or a million marrow cells. It is the best predictor of long survival and, since 2024, an accepted endpoint for accelerated approval.

Measured by next-generation flow (EuroFlow) or NGS (clonoSEQ) on bone marrow, increasingly with imaging (PET) confirmation. FDA ODAC voted 12-0 in April 2024 that MRD negativity at 12 months can support accelerated approval. Sustained MRD negativity (≥12 months) is the strongest prognostic marker; MRD-guided de-escalation of maintenance is being tested (DRAMMATIC, MASTER).

Endpoints: what this kind of term is about · animated schematic, not to scale
Category
Endpoints

Key papers

4top
rctNature Medicine 2025changed practice
CEPHEUS: daratumumab quadruplet for newly diagnosed myeloma patients not having a transplant, with MRD-negativity as the main endpoint

CEPHEUS extends the quadruplet standard to patients who are not going to transplant, closing the gap between transplant-eligible and ineligible populations. It is also one of the first phase 3 trials to be designed around MRD-negativity as the primary endpoint, which could shorten future myeloma trials by years. Frailer patients still need dose-adapted approaches.

rctNew England Journal of Medicine 2024changed practice
PERSEUS: daratumumab added to bortezomib-lenalidomide-dexamethasone around autologous transplant in newly diagnosed myeloma

PERSEUS, with the earlier GRIFFIN and CASSIOPEIA trials, made a four-drug daratumumab quadruplet the standard for fit patients heading to transplant. It also introduced MRD-directed stopping of the antibody, a step towards treatment that is deep but not indefinite. Whether transplant itself remains necessary on top of a quadruplet is now the open question.

rctNew England Journal of Medicine 2023changed practice
CARTITUDE-4: cilta-cel CAR-T versus standard combinations after one to three prior lines of myeloma therapy

CARTITUDE-4 is the first randomised trial to show that a CAR-T improves survival in myeloma, and it moved cilta-cel into second-line use (FDA approval 2024). For patients whose disease returns after first-line lenalidomide, a one-off cell therapy now competes with continuous drug combinations. Capacity, cost and the need for bridging therapy still limit who actually receives it.

rctNew England Journal of Medicine 2019changed practice
MAIA: adding daratumumab to lenalidomide-dexamethasone for older patients with newly diagnosed myeloma who cannot have a transplant

MAIA made a daratumumab-based triplet the standard first treatment for older or frail myeloma patients, replacing Rd alone. It proved an anti-CD38 antibody could improve survival, not just delay progression, when used up front. Quadruplets built on this backbone are now being tested in the same population.

Connected

14top

Pages like this

not linked directly; found by shared links